BigHat Biosciences

Better biologics faster through ML-guided design

BigHat Biosciences designs safer, more effective antibody therapies for patients using machine learning and synthetic biology.

Mission

Our MillinerTM platform integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies.

We apply these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.

01.
Antibody Discovery & Engineering

Full-stack antibody discovery and engineering

BigHat’s Milliner platform integrates a synthetic biology-based high-speed wet lab with state-of-the-art machine learning technologies into a full-stack antibody discovery and engineering platform.

02.
Better Antibodies Faster

Better antibodies faster

Hundreds of recombinant antibodies can be synthesized, purified, and fully characterized for biophysics and function in a single, weekly workcell.

03.
Targeting Intractable Diseases

For today’s most challenging diseases

Antibodies are some of the most powerful and successful medicines for diseases from infections to cancers. Next-generation therapies promise greater safety and efficacy for patients with rational molecular design.

company

Who we are

At BigHat, we have a high-performance culture of excellence, but also pride ourselves on our work/life balance and family-friendly culture.

We’re a Series B biotech outside San Francisco with a pipeline of wholly-owned and partnered therapeutic programs. We’ve raised >$100M from top investors to pursue our vision to create safer, more effective antibody therapies for patients using machine learning and synthetic biology.

PARTNER

Partner with us

BigHat engages with strategic partners to tackle complex protein therapeutic design challenges.